{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '45', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'The effect of combining lenvatinib with an antihuman PD-1 humanized mAb was', 'investigated in 4 murine tumor isograft models, which showed significant tumor growth', 'inhibition compared with control. In the RAG murine tumor isograft tumor model, survival', 'in the group treated with the combination was significantly longer than that of the respective', 'monotherapy groups. In the CT26 murine tumor isograft model, treatment with the', 'combination significantly increased the population of activated cytotoxic T-cells compared', 'with that of the respective monotherapy groups [Kato, Y., et al 2019]. All treatments were', 'well tolerated and severe body weight loss was not observed.', '2.2.2', 'Preclinical and Clinical Studies', '2.2.2.1', 'Completed Studies With Pembrolizumab and Lenvatinib', 'Refer to the respective IBs for further information on completed studies with lenvatinib and', 'pembrolizumab.', '2.2.3', 'Ongoing Clinical Studies of Pembrolizumab and Lenvatinib', 'Pembrolizumab is under evaluation in patients with NSCLC as monotherapy and in', 'combination with chemotherapy, immunotherapy, and targeted therapies. Lenvatinib is being', 'studied in patients with different types of solid tumors, including NSCLC, and in', 'combination with other therapies, including PD-1-targeted therapies. A full list of ongoing', 'studies can be found in the respective IBs of pembrolizumab [IB Edition 16 2018] and', 'lenvatinib [IB Edition 15-Eisai 2018]. Details of the ongoing study 111/KEYNOTE-146 are', 'outlined below.', 'Study 111/KEYNOTE-146', 'Study 111/KEYNOTE-146, is a multicenter, open-label, Phase 1b/2 clinical study to evaluate', 'the efficacy and safety of lenvatinib in combination with pembrolizumab. The primary', 'objective of the Phase 1b portion of the study is to determine the MTD in participants with', 'unresectable solid tumors (endometrial cancer, melanoma, NSCLC, RCC, squamous cell', 'carcinoma of the head and neck, and urothelial cancer) who have progressed after treatment', 'with approved therapies or for which there are no available standard effective therapies. The', 'primary endpoint of the initial part of Phase 2 is ORR after 24 weeks of treatment, with select', 'secondary endpoints, including OR, DCR, PFS, and duration of response (DOR).', 'As of the data cutoff of 01-DEC-2017, 20 participants with NSCLC were enrolled (data on', 'file). Of the enrolled participants, 9 (45%) were PD-L1(+) (TPS 1%), 5 (25%) were', 'PD-L1(-), and 6 (30%) were not tested; 3 (15%) were treatment-na\u00efve; and 6 (30%),', '9 (45%), and 2 (10%) had 1, 2, and >3 prior lines of systemic therapy, respectively. The', 'primary endpoint of ORR at Week 24 was 30.0% (95% CI, 11.9%-54.3%). Grade 3 and 4', 'treatment-related AEs occurred in 11 participants (55%) and 1 participant (5%), respectively', '(ie, increased aspartate aminotransferase [AST]). There was 1 fatal treatment-related AE', '(exsanguination that was deemed possibly related to study intervention). The most common', 'Grade 3 treatment-related AEs were hypertension (30% [6 of 20 subjects]) and fatigue,', 'diarrhea, and hyponatremia (15% [3 of 20 subjects]). These findings indicate that the', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '46', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'combination of lenvatinib with pembrolizumab shows promising clinical activity with a', 'manageable safety profile in previously treated patients with metastatic NSCLC who were', 'not preselected for PD-L1 status.', '2.3', 'Benefit/Risk Assessment', 'NOTE: Data from an interim safety and futility eDMC for LEAP-007 (data cutoff:', '19-MAY-2021) indicated that the study met the prespecified nonbinding futility criteria', 'for OS for the combination of lenvatinib plus pembrolizumab compared with placebo', 'plus pembrolizumab and the benefit-risk assessment was not considered positive to', 'continue the study as designed. Therefore, the benefit-risk assessment of', 'pembrolizumab plus lenvatinib is no longer applicable and has been removed from this', 'section.', 'It cannot be guaranteed that participants in clinical studies will directly benefit from', 'treatment during participation, as clinical studies are designed to provide information about', 'the safety and effectiveness of an investigational medicine.', 'Additional details regarding specific benefits and risks for participants participating in this', 'clinical study may be found in the accompanying IB and informed consent documents.', '3', 'HYPOTHESES, OBJECTIVES, AND ENDPOINTS', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. All participants remaining on study will continue on open-label', 'pembrolizumab monotherapy. No further analyses of efficacy endpoints will be', 'performed. Exploratory objectives may not be pursued.', 'Participants were screened for up to 28 days, then randomized, and continued study', 'treatment until discontinuation (defined in Section 7.1) OR stop/unblinding of study', 'intervention due to the futility analysis criterion for OS being met.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}